Not actual patient.
Not actual patient.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.
Not actual patient.
Currently, most children who receive platinum-based chemotherapy, such as cisplatin, develop hearing loss.
What is cisplatin-induced hearing loss?
Not actual patient.
Not actual patient.
In clinical studies, PEDMARK significantly reduced the number of children who had hearing loss due to cisplatin-based cancer treatment when compared with those who did not receive PEDMARK.
Not actual patient.
Not actual patient.
A total of 232 children up to the age of 18 years received PEDMARK in the clinical studies.
Not actual patient.
No generic approved product exists or can be directly compared; PEDMARK is not substitutable with any other STS formulation.
Fennec HEARS™ is your single source for both financial and patient support. Call 1-833-7PEDMARK.
Find helpful tools for you or your child.
Please see full Prescribing Information, including Patient Information, for PEDMARK.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.
It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.
It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.